Cargando…
High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model
Anticancer potential of metformin has been extensively studied. However, its anticancer clinical use remains yet to be approved since sufficient concentration on target organs could not be achieved via conventional administration. To overcome this drawback, we aim to examine the efficiency of novel...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891029/ https://www.ncbi.nlm.nih.gov/pubmed/26802022 http://dx.doi.org/10.18632/oncotarget.6933 |
_version_ | 1782435205489885184 |
---|---|
author | Peng, Mei Su, Qiongli Zeng, Qing Li, Le Liu, Zhihong Xue, Lei Cheng, Yan Huang, Yanjun Tao, Ting Lv, Hongwei Li, Xiaohui Tao, Xiaojun Guo, Peng Chen, Alex F. Yang, Xiaoping |
author_facet | Peng, Mei Su, Qiongli Zeng, Qing Li, Le Liu, Zhihong Xue, Lei Cheng, Yan Huang, Yanjun Tao, Ting Lv, Hongwei Li, Xiaohui Tao, Xiaojun Guo, Peng Chen, Alex F. Yang, Xiaoping |
author_sort | Peng, Mei |
collection | PubMed |
description | Anticancer potential of metformin has been extensively studied. However, its anticancer clinical use remains yet to be approved since sufficient concentration on target organs could not be achieved via conventional administration. To overcome this drawback, we aim to examine the efficiency of novel intravesical treatment of metformin on syngeneic orthotopic preclinical model. Three human and one murine bladder cancer cell lines were tested in vitro for inhibitory sensitivity by MTT and cologenic assays. AMPK pathway including AKT, Erk and S6K was examined by western blot and further explored by regulating activated levels using specific inhibitors. In vivo efficacy was determined by Kaplan-Meier survival curves and measurements of body and bladder weights plus tumor biomarkers. Lactic acid and metformin levels of plasma were measured by standard procedures. The results demonstrated that metformin activated AMPK and decreased phosphorylation of Akt and Erk. Furthermore, combinations of metformin with either Akt or Erk inhibitors synergistically diminished cancer proliferation, suggesting the involvement of Akt- and Erk- related pathways. Intravesical metformin 26 and 104 mg/kg, twice per week demonstrated a rapid elimination of the implanted tumor without any evidence of toxicity. In contrast, oral treatment at a dose of 800mg/kg/d exhibited little efficacy whereas severe toxicity existed if the dosage is higher. Collectively, intravesical metformin displays potent inhibition on bladder cancer in vitro and this preclinical study reveals the profound therapeutic application of metformin with durable tolerance via intravesical administration route. |
format | Online Article Text |
id | pubmed-4891029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-48910292016-06-20 High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model Peng, Mei Su, Qiongli Zeng, Qing Li, Le Liu, Zhihong Xue, Lei Cheng, Yan Huang, Yanjun Tao, Ting Lv, Hongwei Li, Xiaohui Tao, Xiaojun Guo, Peng Chen, Alex F. Yang, Xiaoping Oncotarget Research Paper Anticancer potential of metformin has been extensively studied. However, its anticancer clinical use remains yet to be approved since sufficient concentration on target organs could not be achieved via conventional administration. To overcome this drawback, we aim to examine the efficiency of novel intravesical treatment of metformin on syngeneic orthotopic preclinical model. Three human and one murine bladder cancer cell lines were tested in vitro for inhibitory sensitivity by MTT and cologenic assays. AMPK pathway including AKT, Erk and S6K was examined by western blot and further explored by regulating activated levels using specific inhibitors. In vivo efficacy was determined by Kaplan-Meier survival curves and measurements of body and bladder weights plus tumor biomarkers. Lactic acid and metformin levels of plasma were measured by standard procedures. The results demonstrated that metformin activated AMPK and decreased phosphorylation of Akt and Erk. Furthermore, combinations of metformin with either Akt or Erk inhibitors synergistically diminished cancer proliferation, suggesting the involvement of Akt- and Erk- related pathways. Intravesical metformin 26 and 104 mg/kg, twice per week demonstrated a rapid elimination of the implanted tumor without any evidence of toxicity. In contrast, oral treatment at a dose of 800mg/kg/d exhibited little efficacy whereas severe toxicity existed if the dosage is higher. Collectively, intravesical metformin displays potent inhibition on bladder cancer in vitro and this preclinical study reveals the profound therapeutic application of metformin with durable tolerance via intravesical administration route. Impact Journals LLC 2016-01-18 /pmc/articles/PMC4891029/ /pubmed/26802022 http://dx.doi.org/10.18632/oncotarget.6933 Text en Copyright: © 2016 Peng et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Peng, Mei Su, Qiongli Zeng, Qing Li, Le Liu, Zhihong Xue, Lei Cheng, Yan Huang, Yanjun Tao, Ting Lv, Hongwei Li, Xiaohui Tao, Xiaojun Guo, Peng Chen, Alex F. Yang, Xiaoping High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model |
title | High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model |
title_full | High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model |
title_fullStr | High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model |
title_full_unstemmed | High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model |
title_short | High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model |
title_sort | high efficacy of intravesical treatment of metformin on bladder cancer in preclinical model |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891029/ https://www.ncbi.nlm.nih.gov/pubmed/26802022 http://dx.doi.org/10.18632/oncotarget.6933 |
work_keys_str_mv | AT pengmei highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT suqiongli highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT zengqing highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT lile highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT liuzhihong highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT xuelei highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT chengyan highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT huangyanjun highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT taoting highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT lvhongwei highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT lixiaohui highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT taoxiaojun highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT guopeng highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT chenalexf highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel AT yangxiaoping highefficacyofintravesicaltreatmentofmetforminonbladdercancerinpreclinicalmodel |